Histone deacetylase (HDAC) inhibitors induce an intrinsic type of apoptosis in human papillomavirus (HPV)-positive cells by disrupting the mitochondrial transmembrane potential (DW m ). Loss of DW m was only detected in E7, but not in E6 oncogene-expressing cells. HDAC inhibition led to a time-dependent degradation of the pocket proteins pRb, p107 and p130, releasing 'free' E2F-1 following initial G1 arrest. Inhibition of proteasomal proteolysis, but not of caspase activity rescued pRb from degradation and functionally restored its inhibitory effect on the cyclin E gene, known to be suppressed by pRb-E2F-1 in conjunction with HDAC1. Using siRNA targeted against p53, E2F-1 still triggered apoptosis by inducing the E2F-responsive proapoptotic a-and b-isoforms of p73. These data may determine future therapeutic strategies in which HDAC inhibitors can effectively eliminate HPVpositive cells by an apoptotic route that does not rely on the reactivation of the 'classical' p53 pathway through a preceding shut-off of viral gene expression.
Introduction
Apoptosis is an important defense mechanism through which damaged or virus-infected cells are eliminated. Hence, disturbance of this homeostatic process underlies many serious clinical disorders including cancer (Krammer, 2000) . Two principal apoptotic pathways have been defined to date. Type I or extrinsic apoptosis involves transmembrane death receptors, a subset of the TNF-R/NGF-R superfamily, comprising CD95 (APO-1/Fas), TNF-R1 (CD120a) and TRAIL-R1/2 (DR4/5) Igney and Krammer, 2002) .
Receptor interactions with their corresponding ligands trigger the assembly of multiple submembrane protein complexes ( ¼ death-inducing signaling complex, 'DISC') and the autocatalyic activation of the initiator procaspase-8 (Walczak and Krammer, 2000) . The intrinsic or type II pathway is mediated via the mitochondria and acts as an integrating sensor of multiple death insults, such as DNA damage, cellular stress and growth factor withdrawal (Vander Heiden et al., 2000; Van Loo et al., 2002) . Induction of apoptosis at this level operates through mitochondrial membrane potential breakdown, release of cytochrome c, activation of Apaf-1 and procaspase-9 at the apoptosome (Igney and Krammer, 2002) . Despite their initial separation, the two pathways converge, leading to the proteolytic cleavage of the executioner procaspase-3 and the appearance of the typical apoptoptic cell morphology such as membrane blebbing, nuclear condensation and DNA fragmentation (Hengartner, 2000) . Intrinsic type II apoptosis is primarily modulated by Bcl-2 protein family members, which include both proapoptotic (e.g. Bax, Bak, Bad) and antiapoptotic proteins (e.g. Bcl-2, Bcl-x L ) (Van Loo et al., 2002) .
The accumulation of cancer cells is not only associated with apoptotic dysfunction but also with deregulated cell proliferation (Green and Evan, 2002) . Here, the retinoblastoma protein (pRb) has a linking function between regulation of cell cycle progression and cell survival (Harbour and Dean, 2000) . pRb can inhibit proliferation by modulating the activity of E2F transcription factors. pRb interacts with E2F-1, E2F-2 and E2F-3, which results in repression of E2F-responsive proliferation-associated genes (Dyson et al., 1989) . As the cell cycle progresses, E2F becomes dissociated from hyperphosphorylated pRB and transactivates the genes required for S-phase entry (Harbour and Dean, 2000) . In addition to the proliferative effects, E2F-1 is also involved in apoptosis (Nevins, 1998) .
A key role of pRb-E2F in controlling cell proliferation and apoptosis is reflected by the fact that this pathway is disrupted in virtually all human cancers (Nevins, 1998) . In cervical carcinomas, which represent the second most frequent gynecological malignancy worldwide (Pisani et al., 2002) , pRb is deregulated by the human papillomavirus (HPV) E7 oncogene, which results in the unscheduled transcriptional activation of E2F target genes (Dyson et al., 1989; Hwang et al., 2002) . Since malignant growth arises from the simultaneous occurrence of deregulated cell proliferation and suppressed apoptotic signals (Green and Evan, 2002) , it is striking that inhibitors of the histone deacetylase (HDAC) can efficiently revert both of these pathways in HPV-positive cancer cells (Finzer et al., 2001) . Notably, HPV expression is still ongoing under these conditions, although it was hitherto thought that viral transcription first has to be abrogated in order to block cell proliferation (Bernard, 2002) . Upon HDAC inhibition, however, viral oncoprotein function became completely neutralized by increased expression of the cyclindependent kinase (cdk) inhibitors p21CIP1 and p27KIP1 and concomitant suppression of cdk2 activity (Finzer et al., 2001) . Investigating various additional immortalized and malignant HPV-positive cells, G1 arrest and preceding cdk2 inhibition were found to be general effects and independent of the HPV type, the copy number and the integration locus of the viral DNA (Finzer et al., 2002 (Finzer et al., , 2003 . In a second step, prolonged incubation with HDAC inhibitors finally induced apoptosis, apparently due to the expression of Sphase-specific genes under conditions where G1 arrest was accomplished (Finzer et al., 2001) .
In the present study, we demonstrate that HDAC inhibitors induce apoptosis in HPV-positive cervical carcinoma cells through the mitochondrial pathway, leading to an E7-dependent breakdown of the transmembrane potential. HDAC inhibition mediated a timedependent degradation of the pocket proteins pRb, p107 and p130 and an intracellular accumulation of 'free' E2F-1. This, in turn, strongly induced the expression of the proapoptotic isoforms of the p53 homologue p73, providing a functional link between the presence of free E2F-1 during growth arrest and the subsequent generation of apoptotic cells. This offers a potential strategy in future therapeutic approaches to eliminate suspicious HPV-positive cells without reactivating p53 as the main executor of apoptosis.
Results

HDAC inhibition induces apoptosis via the mitochondrial pathway
As revealed by microscopic examination, treatment of cervical carcinoma cells (HeLa) with sodium butyrate (NaB) for 24 h led to the appearance of typical apoptotic figures with condensations of the cytoplasm and fragmentation of the nuclear chromatin ( Figure 1a ).
To quantify to what extent apoptosis was dependent on the duration of drug application, flow-cytometric analyses were performed. Figure 1b shows that about 5% of the cell population accumulated within the sub-G1 fraction 24 h after NaB incubation and raised up to more than 40% when incubation time was extended to 48 h. Similar results were obtained using TSA as HDAC inhibitor (data not shown). To test whether apoptosis was executed via an extrinsic ( ¼ type I) or an intrinsic ( ¼ type II) pathway , we measured the mitochondrial transmembrane potential (DC m ) (Van Loo et al., 2002) . The assessment of DC m in intact cells was carried out using the lipophilic cationic probe JC-1 as a fluorescent dye (Salvioli et al., 1997) . It is noteworthy that although only 5% of the cell population was present in sub-G1 24 h after adding NaB (Figure 1b) , apparently more cells were already committed to apoptosis, since 15-20% of the cell population showed a strong breakdown of the mitochondrial membrane potential (DC m ) (Figure 2a) . Loss of DC m was accompanied by the release of cytochrome c from the inner mitochondrial space into the cytosol (data not shown). Sensitivity to apoptosis and activation of mitochondria can be modulated by molecules belonging to the Bcl-2 family (Cory and Adams, 2002) . However, HDAC inhibition neither significantly decreased the amount of the antiapoptotic proteins Bcl-2 and Bcl-xL To determine whether the loss of DC m upon HDAC inhibition could be attributed to different biochemical properties of the viral oncoproteins, we used human keratinocytes immortalized with amphotropic retroviruses separately encoding E6 or E7 from HPV 16. As shown previously, E7-positive cells were highly susceptible to undergo apoptosis upon NaB and TSA treatment, whereas E6-expressing keratinocytes were completely resistant under the same experimental conditions (Finzer et al., 2001) . In accordance with these results, Figure 2b revealed that only E7-expressing cells showed a loss of DC m 24 h after NaB treatment (approximately 20%), while E6-immortalized keratinocytes were not affected. These data suggest the existence of an E7-dependent mode of apoptosis without quantitative changes of the above mentioned Bcl-2 family members.
HDAC inhibitors do not change the expression of cell surface-associated death receptors Disruption of the mitochondrial transmembrane potential can also be induced via the extrinsic (type I) apoptosis signaling after ligand binding and 'DISC' formation (Igney and Krammer, 2002) . To exclude this pathway, CD95 and TRAIL-R1/2 surface expression was examined by immunolabeling and flow cytometry. Figure 3a demonstrates that the number of immunoreactive CD95 and TRAIL-R2 receptor sites remained unchanged after HDAC inhibition, whereas TRAIL-R1 was even slightly decreased. Furthermore, to rule out that HDAC inhibitors mediate apoptosis by enhanced secretion of particular death-receptor ligands, HeLa cells were incubated with NaB in the presence of neutralizing receptor-Ig fusion proteins directed against CD95L, TRAIL and TNF-a. Under these conditions, the degree of apoptosis was not diminished when compared with cells treated with HDAC inhibitor alone (data not shown). Consistent with this notion was also the finding that procaspase-8 was not cleaved when cellular extracts were examined by Western blot (Figure 3b ). These data demonstrate that HDAC inhibitors induced apoptosis in HPV-positive cells exclusively via the intrinsic pathway.
Selective degradation of the pocket proteins pRb, p107 and p130 after HDAC inhibition
In order to elucidate how intrinsic cell death was induced, we focused our attention on half-life control of pRb. As previously reported (Finzer et al., 2001) , HDAC inhibitors initially caused G1 arrest prior to apoptosis, which was preceded by complete inhibition of cdk2 activity. Under these conditions, pRb was found to be absent despite constant E2F-1 levels. The absence of pRb was strictly dependent on the presence of the E7 oncoprotein because in apoptosis-resistant, yet growtharrested E6-immortalized human keratinocytes, pRb was hypophoshorylated. Since pocket proteins such as pRb, p107 and p130 normally suppress the activity of E2F family members by masking their transactivation domains during G1 (Harbour and Dean, 2000; Classon and Dyson, 2001) , we anticipated that the unscheduled release of E2F-1 under growth arrest conditions might favor apoptosis.
To prove whether apoptosis correlated with pRb degradation, kinetic experiments were performed. Figure 4a shows that the degradation already started between 12 and 16 h and that pRb was almost no longer detectable 20 h after adding NaB. p107 was also diminished under the same conditions, while the level of E2F-1 remained constant. These data were consistent with our previous observation, detecting the onset of apoptosis exactly within this time frame using a highly sensitive ELISA assay to measure the release of histones into the cytoplasm after nuclear breakdown (Finzer et al., 2001) . Furthermore, monitoring quantitative changes of additional pocket proteins 24 h after NaB treatment, p130 was also reduced (Figure 4b ). Similar to that of E2F-1, the amount of E2F-4 as the major interaction partner of p130 was not affected either ( Figure 4b ). The presence of 'free' E2F-1 in nuclear extracts could be confirmed in electrophoretic mobility 'super-shift' assays (EMSAs) after adding E2F-1 antibodies specifically raised against the pRb-binding domain. Using an oligonucleotide containing the consensus-binding site for E2F-1, a relatively weak signal of 'free' E2F-1 was detected in nuclear extracts obtained from nonsynchronized control cells ( Figure 4c , lane 2). Conversely, after incubation with NaB, adding antibody resulted in a band with slower mobility, indicating unbound E2F-1 (Figure 4c , lane 4). In agreement with our previous study (Finzer et al., 2001) , the same results were obtained with TSA-treated cells (data not shown). On the basis of these observations, it was reasonable to assume that E2F-1 acts as a key factor in mediating intrinsic cell death after degradation of the pocketbinding proteins pRb/p107 and -to a lesser extentp130.
Degradation of pRb can be prevented by inhibition of the proteasome but not by pancaspase inhibitors
Since the half-life of pocket proteins is normally controlled by the 26S proteasome (Boyer et al., 1996) , the fate of pRb was monitored in the presence of MG132, an inhibitor of the proteasome pathway (Rock et al., 1994) . For this purpose, HeLa cells were treated with NaB either in the absence or in the presence of different concentrations of MG132 ( Figure 5a ). Although there were no major changes in the steadystate level of E2F-1 (lanes 1-6), degradation of pRb (lane 2) was completely inhibited by MG132 (lanes 4 and 6). MG132 alone did not increase pRb (lane 3 and 5). To demonstrate that E2F-1 was functional, the expression pattern of the E2F-target gene cyclin E was examined. In agreement with a previous report (Brehm et al., 1998) , cyclin E expression was negatively regulated when E2F-1 is bound to pRb (lane 1), but became clearly activated when pRb was absent (lane 2). In contrast, upon prevention of pRb proteolysis, cyclin E expression remained suppressed (lanes 4 and 6).
During early apoptosis, however, pRb can be also proteolytically cleaved by caspases (Janicke et al., 1996) . Although it is claimed that pRb cleavage is cell specific, e.g. during neuronal apoptosis (Boutillier et al., 2000) , it was mandatory to exclude the involvement of caspases as additional executers in this process. In fact, as depicted in Figure 5b , the pancaspase inhibitor zVADfmk (Tan et al., 1997) had no effect on HDAC-induced pRb degradation. Cyclin E as target gene for 'free' E2F still remained expressed. To prove the functionality of zVAD-fmk under our experimental conditions, cells were incubated with cycloheximide (10 mg/ml) and TNFa (250 U/ml) for 5 h, known to induce efficient and rapid apoptosis in HeLa cells (Aguilar-Lemarroy et al., 2001) . Using poly-(ADP-ribose) polymerase (PARP) as internal marker, PARP cleavage could be completely prevented the presence of 100 mM zVAD-fmk (Figure 5c ). These data confirmed that the intracellular availability of 'free' E2F-1 strictly depends on the absence of pRb, whose degradation was exclusively mediated by the ubiquitin-proteasomal pathway. Degradation of pRb is leading to 'free E2F'. (a) HeLa cells were treated with 6 mM sodium butyrate for the indicated periods of time. Western blot analysis: total cell extracts were separated in 8% (pRb) and 12% SDS-PAGE gels. After electrotransfer, the filters were incubated with antibodies directed against pRb, p107 and E2F-1. Equal loading was confirmed with a monoclonal anti-actin antibody. (b) Western blotting of total HeLa cell extracts treated with 6 mM NaB for 24 h using anti-p130 and anti-E2F-4 antibodies. Equal loading was confirmed with a monoclonal anti-actin antibody. (c) E2F-1 EMSA with nuclear extracts obtained from HeLa cells treated with NaB for 24 h. EMSA was performed either in the absence (À) or presence of an anti-E2F-1 antibody directed against the pRb-binding domain. Contr.: untreated control; NaB: 6 mM sodium butyrate. Nonspecific binding is indicated by an asterisk Apoptosis induction in HPV-positive cells by HDAC inhibitors P Finzer et al HDAC inhibition provokes p53-independent apoptosis by inducing the proapoptotic isoforms of p73
Several E2F-target genes have been identified up to now which could provide a functional link between the presence of 'free' E2F-1 and the induction of intrinsic apoptosis (Trimarchi and Lees, 2002) . A prime candidate is the Apaf-1 gene encoding the apoptosis proteaseactivating factor . However, Northern blot analysis failed to reveal any upregulation of Apaf-1 under conditions where cyclin E was found to be elevated (data not shown). Furthermore, there was no detectable accumulation of p53 even after longer incubation with HDAC inhibitors (Figure 6a ), while the cdk inhibitor p21CIP1, mediating cdk2 suppression and cell cycle arrest, remained induced (Finzer et al., 2001 (Finzer et al., , 2002 . Since it has been reported that HDAC inhibition enhances p53 transactivation-dependent apoptosis through acetylation (Luo et al., 2000) , we used specific siRNA to knock down the residual amounts of p53 in HeLa cells (Brummelkamp et al., 2002) . As shown in Figure 6b by Western blot analysis, transfection of a p53 pSUPER-vector completely suppressed p53 both in nontreated and in NaB-treated cells (Figure 6b , lanes 5 and 6), while the empty vector showed no changes on p53 expression when compared with mock transfected cells (lanes 3 and 4) . To assess whether p53 suppression also reduces the induction of apoptosis by HDAC inhibitors, flow cytometric analyses were performed to quantify the percentage of cells within the sub-G1 peak. As given in Figure 6c , a similar proportion of HeLa cells underwent apoptosis independently of whether p53 was expressed or not (14.4 vs 15.8%).
These data unequivocally demonstrate that HDAC inhibition provoked an E2F-1 triggered mode of apoptosis, which was completely independent of p53. However, when we investigated the p53 homologue p73 (Irwin et al., 2000) , another known target of E2F-1, a completely different picture emerged. The p73 gene encodes a complex pattern of differentially spliced mRNA species from which only transcripts, harboring the transactivating domain (exons 1-3), were translated to proteins with proapoptotic function. These kinds of mRNAs are initiated from an upstream E2F-responsive regulatory region (designated as promoter TA). Conversely, the class of transcripts coding for the antiapoptotic proteins are initiated from the downstream promoter DN (Melino et al., 2002 ; see also the schematic overview in Figure 7a) . To dissect the different p73 isoforms, reverse transcription-PCR (RT-PCR) analyses were performed. The use of a defined set of primers (derived from the second and the 14th exon as well as from a conserved region characteristic for DNp73 transcripts) enabled us to distinguish between the various splicing variants. As shown in Figure 7b , there was a time-dependent induction of TAp73a and b, representing the two proapoptotic isoforms of p73 (Yang et al., 2002) . Transcription was maximal after 16 h, temporally coinciding with the complete disappearance of pRb (Figure 4a ). The levels of TAp73a and b declined 24 h after NaB treatment, which was consistent with the delayed accumulation of the antiapoptotic DNp73a mRNA. This splice variant acts in turn via a negative regulatory loop at the p73-responsive TA promoter (Yang et al., 2002) . These data indicate that HDAC-induced apoptosis was mediated by a p53-independent pathway by an E2F-1 activation of the proapoptotic forms of p73 after pRb degradation.
Discussion
The transforming function of high-risk HPVs is encoded by the viral oncoproteins E6 and E7 (Mantovani and Banks, 2001; Mu¨nger et al., 2001) . Despite their low molecular weight, they exert pleiotropic effects on infected cells, both at the transcriptional and the translational level (Nees et al., 2001; zur Hausen, 2002) . Accordingly, in terms of therapy, strategies must be developed that block either viral transcription directly or that ablate the function of pre-existing oncoproteins. In our attempt to treat premalignant and malignant HPV-positive cells, we used inhibitors of the HDACs, which can arrest cells at G1 to S transition by entirely circumventing viral oncogene function (Finzer et al., 2001 (Finzer et al., , 2002 .
In the present study we have further demonstrated that NaB (and TSA) provoked intrinsic (type II) apoptosis in HPV-positive cells in a time-dependent manner (Figure 1 ). Apoptosis was preceded by an early breakdown of the mitochondrial transmembrane potential (DC m ) (Figure 2a ). Mitochondrial integrity upon apoptotic signaling is controlled by members of the Bcl-2 family (e.g. Bcl-2, Bcl-xL, Bax or Bak) (Cory and Adams, 2002) . However, when examining their expression levels, none of these Bcl-2 members showed significant quantitative changes upon NaB treatment (data not shown). Mitochondrial damage and loss of the transmembrane potential DC m were apparently an E7 oncogene-specific trait (Figure 2b ) corroborating our previous observation that pRb degradation and apoptosis occurred only in immortalized human keratinocytes expressing E7, but not in E6-positive cells (Finzer et al., 2001) .
Raising the question by which apoptotic pathway the cells finally were eliminated, it has been shown that certain antineoplastic drugs such as 5-fluorouracil or etoposide cause type I apoptosis in their target cells by either upregulating CD95 or its corresponding ligand Eichhorst et al., 2000) . Since expression of the death receptors CD95 and TRAIL- R1/2 was not significantly changed upon prolonged HDAC inhibitor application, additional or synergistic surface signaling could be excluded (Figure 3a) . However, the mere absence of quantitative alterations of death receptor expression is not necessarily a reliable predictive marker of the biological outcome of an apoptotic response (Re et al., 2000) . It is also conceivable that HDAC inhibitors may augment death ligand expression (Eichhorst et al., 2000) . In order to exclude this possibility, treated cells were coincubated with neutralizing antibodies against CD95L, TRAIL and TNF-a, but apoptosis could not be prevented (data not shown). In line with these data was the fact that procaspase-8, normally activated upon ligand engagement, was not autocatalytically cleaved when the cells were exposed to HDAC inhibitors (Figure 3b ). Supporting data recently reported for lymphatic cells (Rosato et al., 2003) , these results also demonstrate that exclusively an intrinsic form (type II) of apoptosis was induced ( Figure 2a) . A functional link between the E7 oncogene-dependent mitochondrial transmembrane breakdown DC m ( Figure 2b ) and type II apoptosis (Figure 3 ) was provided by the selective degradation of pRb, p107 and p130 and the concomitant maintenance of E2F-1 expression (Figure 4 ). Similar to pRb, p107 and p130 are also capable of blocking transcriptional activation of free E2Fs and can interact with HDAC1 to repress E2F-responsive genes (Ferreira et al., 1998) . However, whereas pRb interacts mainly with E2F-1, E2F-2, E2F-3 and E2F-4, respectively, p107 and p130 primarily associate with E2F-4 and E2F-5 (Classon and Dyson, 2001) . Unlike p107 and p130, which were not frequently found to be mutated in human cancer, pRb acts not only as a transcriptional corepressor that controls cell cycle progression (Harbour and Dean, 2000) , but is also associated with increased rates of apoptosis in pRbdeficient cells (Almasan et al., 1995) . Depending on the cell system and the external stimulus, pRb can be potentially also cleaved by activated caspase-3 during apoptosis (Boutillier et al., 2000; see below) . While under these experimental conditions pRb only attenuates the apoptotic response (Haas-Kogan et al., 1995) , NaB-mediated pRb degradation was apparently the cause and not the consequence of apoptosis. This notion was not only substantiated by the presence of S-phasespecific E2F-1 throughout cdk2 suppression and G1 arrest (Finzer et al., 2001) , but also by the kinetics of pRb/p107 degradation (Figure 4a ). The transactivating function of 'free' E2F-1 (Figure 4c ) was confirmed by the induction of the cyclin E gene ( Figure 5, lane 2) , which is negatively regulated by pRb-E2F-1 in combination with HDAC1 (Brehm et al., 1998) .
Since the metabolic half-life of pRb is inherently controlled by E7 (Boyer et al., 1996) , its enforced intracellular degradation upon HDAC inhibition (Figure 4a ) also diminished its antiapoptotic activity (Haas-Kogan et al., 1995) . Notably, a recent study has shown that E7 can also interact with E2F-1 in a pRbindependent fashion, thereby augmenting its proapoptotic activity. In this constellation, expression of both proteins in pRb-negative cells resulted in stronger apoptosis than with E2F-1 alone (Hwang et al., 2002) . These data are related to our previous observation that pRb degradation and apoptosis occurred only in E7 oncogene-expressing cells, but not in their E6-positive counterparts (Finzer et al., 2001) . Hence, at least in this context, maintenance of ongoing E7 oncoprotein expression (Finzer et al., 2002 (Finzer et al., , 2003 even seems to be beneficial in terms of the therapeutic use of HDAC inhibitors to eliminate HPV-positive cells via intrinsic apoptotic stimuli. Since pRb only became hypophosphorylated in other cell systems upon HDAC inhibition (Wang et al., 2000; Wharton et al., 2000) , it will be the objective of further studies to analyse the fate of pRb and the extent of apoptosis in HPV-negative cells prior to and after delivery of E7-expression vectors.
pRb degradation was obviously triggered by the proteasomal pathway ( Figure 5a , lane 2), because MG132 restored its half-life to levels initially expressed before NaB treatment (Figure 5a) . Notably, simultaneous MG132/NaB merely resulted in an accumulation of hypophosphorylated pRb. This was likely due to the fact that, similar to E2F (see below), pRb is also posttranslationally controlled via acetylation through binding to p300/CBP, a transcriptional adaptor molecule with intrinsic histone acetyltransferase (HAT) activity. Hence, NaB treatment switches the HAT/HDAC equilibrium within the pRb complex in favor of HAT. In that way, acetylation at the lysine residues at positions 830 and 884 is enhanced, which inhibits pRb phosphorylation (Chan et al., 2001 ) and, in turn, increases the appearance of hypophosphorylated pRb after MG132 application. Unfortunately, prevention of pRb degradation did not rescue cells from cell death (data not shown), since long-term incubation with MG132 per se already induced apoptosis (Lin et al., 1998; Meriin et al., 1998) . Nonetheless, restoration of threshold levels of hypophosphorylated pRb upon simultaneous NaB/MG132 application was evidently sufficient to sequester 'free' E2F-1 and to re-establish the inhibitory function on cyclin E expression (Figure 5a , compare lanes 2 and 6, respectively).
During apoptosis, pRb is also subjected to cleavage near the carboxyl terminus by a caspase-3-like protease, which abrogates the ability of pRb to bind E2F (Boutillier et al., 2000) . However, as shown in Figure 5b , degradation was completely independent of caspase activity, since the pancaspase-inhibitor zVADfmk neither rescued pRb from degradation nor resuppressed cyclin E expression upon HDAC inhibitor treatment.
How does HDAC inhibition induce apoptosis in HPV-positive cells? HDAC inhibitors may act through an E2F-1-triggered, p53-dependent pathway during which p14 ARF , a known E2F-responsive gene (Bates et al., 1998) , becomes transcriptionally activated. p14 ARF can interact with the E3 ubiquitin ligase Hdm2, which finally blocks Hdm2 to target p53 to proteasomedependent degradation (Pomerantz et al., 1998; Zhang et al., 1998) . This possibility, however, could be ruled out because the amount of p53 was not changed and remained constant for up to 32 h in the presence of HDAC inhibitors and elevated levels of p21CIP1. (Figure 6a ). In fact, p14 ARF is not automatically involved in this kind of cell death because E2F-1 can also induce apoptosis in cells lacking p14 ARF (Rogoff et al., 2002) . However, although p53 was not significantly affected in its quantity upon HDAC inhibition (Figure 6a) , the protein is still subjected to post-translational modification mechanisms such as phosphorylation and acetylation by particular stress kinases (e.g. ATM, ATR, Chk1 or Chk2) or deacetylases (e.g. PID or hSir2) (for a review, see Brooks and Gu, 2003) . In both cases, it was conceivable that even though the level was inherently reduced due to the presence of the E6 oncoprotein (for a review, see zur Hausen, 2002), p53 could still participate in apoptosis. To exclude this possibility, we took advantage of a new vector system, named pSUPER, which efficiently directs the synthesis of an siRNA against p53 (Brummelkamp et al., 2002) . As shown in Figure 6b and c, independently of whether the cells were transfected with p53 siRNA or not, NaB induced the same rate of apoptosis, which was measured by quantifying the number of sub-G1 cells by flowcytometry. These data unambiguously demonstrate that HDAC-induced apoptosis was completely independent from p53.
DNA chip analyses have unraveled many target genes, whose transcription becomes elevated when E2F-1 is switched on by inducible systems (Phillips et al., 1999; Mu¨ller et al., 2001; Stanelle et al., 2002) . However, similar to p14 ARF , neither Apaf-1 ) nor Bcl-2 (Gomez-Manzano et al., 2001 , all identified as potential E2F-1 target genes, were elevated upon NaB treatment using HeLa cell cDNAs as labeled probes for microarray analyses (data not shown). This once again supports the notion that the range of induced E2F target genes found in one cell line is not essentially transferable to other systems (Stanelle et al., 2002) .
Free E2F-1, which was released after pRb degradation, however, can also cause apoptosis in a p53-independent manner via the p53 homologue p73 (Phillips and Vousden, 2001 ). While p53 is posttranslationally stabilized by Hdm2 and p14, E2F-1-induced elevation of p73 acts exclusively at the transcriptional level through E2F-1 binding to responsive sites within the p73 TA promoter (Irwin et al., 2000) . Since the p73 gene encodes a complex pattern of different splicing intermediates, we used RT-PCR primers to distinguish between proapoptoptic transcripts derived from TA and antiapoptotic mRNA species originating from the downstream DN promoter (Yang et al., 2002) . As depicted in Figure 7b , there was a time-dependent accumulation of the two proapoptotic isoforms TAp73a and b, whose transcription reached maximum levels 16 h after NaB treatment. The delayed appearance of DNp73a transcript indicates that the positive regulatory loop on the p73-responsive sites within the DN promoter was functional (Melino et al., 2002) . DNp73a in turn negatively regulates the TA promoter, finally accounting for reduced expression of TAp73a and b after 24 h. It is also noteworthy that 4 h after NaB addition TAp73a and b were already expressed when pRb could still be detected (see Figure 4a ). This may be explained by the fact that preexisting E2F acts as a substrate for acetylation through its interaction with p300/CBP-associated factor P/CAF. Acetylated E2F-1 increases not only its transactivation potential but also its intracellular half-life (MartinezBalbas et al., 2000) . Both effects, however, can be neutralized by antagonists of this reaction, namely, HDAC-1 (Martinez-Balbas et al., 2000; Marzio et al., 2000) . Similar to the situation described for pRb (see above), inhibition of deacetylation by NaB favors HAT activity, thereby enhancing the activity of pre-existing unbound E2F in nonsynchronized cells.
In conclusion, these results indicate that HDAC inhibition activates an intrinsic death program in cervical carcinoma cells by finally inducing proapoptotic forms of p73. This finding might be of widespread therapeutic relevance, since HDAC inhibitors such as valproic acid or phenylbutyrate are already in clinical use (Marks et al., 2001) . In fact, HDAC inhibitors fulfil a major request for an antitumor agent in HPV-induced carcinogenesis: they first force HPV-positive cells to arrest the cell cycle (Finzer et al., 2002 (Finzer et al., , 2003 and subsequently provoke intrinsic apoptosis by targeting the pRb/E2F-1/p73 pathway without preceding oncogene suppression.
Materials and methods
Cell lines and reagents
The HPV-positive cervical carcinoma cell line HeLa was maintained in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% fetal calf serum (GIBCO, BRL), 1% penicillin and streptomycin (Sigma). Primary human keratinocytes, immortalized by E6-and E7-open reading frames carrying amphotropic retroviruses (Whitaker and zur Hausen, unpublished) were cultivated in serum-free keratinocyte medium 'Keratinocyte-SFM' (GIBCO BRL). The sodium salt of the n-butyric acid (Sigma) was freshly dissolved and diluted with cultivation medium. Trichostatin A (Sigma), MG132 (Calbiochem) and zVAD-fmk (Calbiochem) were dissolved in dimethylsulfoxid (DMSO) (Merck). Apoptosis was induced by treatment of the cells in combination with 10 mg/ml cycloheximide (Sigma) and TNF-a (500 U/ml; Strathmann) as described (Aguilar-Lemarroy et al., 2001).
DNA staining, flow cytometry and quantification of apoptosis Cells were harvested by trypsination, washed twice with phosphate-buffered saline (PBS) and fixed overnight with 70% ethanol. After fixation and centrifugation, the cell pellets were resuspended in DNA staining solution containing DAPI (5 Â 10 À6 M) as the DNA dye and SR 101 (5 Â 10 À6 M) as a protein counter stain following the protocol published by Stoehr et al. (1978) . Processing, cell cycle analysis and quantification of apoptosis of flow cytometric data were performed according to Dean and Jett (1974) .
Semiquantitative RT-PCR
RT-PCR was performed with total RNA extracted by the guanidinium-thiocyanate method (Chomczynski and Sacchi, 1987) . In all, 1.75 mg of RNA was employed for cDNA synthesis in a total volume of 20 ml using SuperScriptt II RNase H -reverse transcriptase (Invitrogen, Life Technologies) and oligo dT (22mer). PCR was performed using 0.5 ml of the RT reaction in a final volume of 25 ml and 5 U/ml Taq DNA polymerase (Invitrogen, Life Technologies): 34 (p73 and GAPDH) or 42 (DNp73) cycles with 30 s at 941C, 30 s at 651C (p73 and GAPDH) or 671C (DNp73) annealing temperature and 1 min at 721C. The following upstream and downstream primers were used for the cDNA encoding p73a, b and g: 5 0 -TGATGGGGGCACCACGTTTGAG-3 0 and 5 0 -TGTAGTCGTGGCCCTGCTTCAG-3 0 , for DNp73 5 0 -GATGGGAAAAGCGAAAATGCCAAC-3 0 and 5 0 -TGTA GTCGTGGCCCTGCTTCAG-3 0 and for glyceraldehyde-3-phosphate dehydrogenase: 5 0 -TGGATATTGTTGCCATCA ATGACC-3 0 and 5 0 -GATGGCATGGACTGTGGTCATG-3 0 (Griffiths et al., 1997) .
SDS-PAGE and Western blots
Whole cellular extracts were separated in 8-12% SDS-PAGE gels and electrotransferred as described elsewhere (Finzer et al., 2001) . The following antibodies were used: E2F-1 (KH95), E2F-4 (RK-13), cyclin E (HE12), p107 (C-18), p130 (C-20), PARP (F-2) from Santa Cruz Biotechnology Inc., p53 (Ab-1) from Oncogene, p21 (Cip/WAF1) (C24420) from Transduction Laboratories and pRb (G3-245), Bcl-2 (7) from BD PharMingen (San Diego CA, USA). The polyclonal antibody against Bcl-x L was purchased from BD Biosciences (Heidelberg, Germany). Monoclonal antibodies against Bax (clone ID3) and Bak (clone TC-100) were purchased from Oncogene (San Diego, CA, USA). The use of anticaspase-8mAb C15 was done as described previously (Scaffidi et al., 1997) . Equal protein transfer and loading was routinely checked by incubating the filters with a monoclonal actin antibody (ICN Biomedicals, Ohio).
Electrophoretic mobility shift assays
To analyse protein/DNA interactions by EMSAs, an oligonucleotide containing a recognition site for E2F-1 (5 0 -ATT-TAAGTTTCGCGCCCTTTCTCAA-3 0 ) was used. The DNA was synthesized using a phosphoramitide chemistry (Applied Biosystems Synthesizer) and further purified by HPLC. Preparation of nuclear extracts was performed exactly as described (Soto et al., 1999) . EMSA was performed in a 12.5 ml reaction volume containing 12 mM HEPES, pH 7.9, 240 mM NaCl, 0.6 mM EDTA, 0.6 mM EGTA, 0.6 mM DTT, 2 mM MgCl 2 , 20 ng/ml salmon sperm DNA and 10 mg nuclear extract. After 5 min, 10 000 c.p.m. of the 32 P-g-ATP 5 0 -end labeled doubled-stranded oligonucleotide was added and incubation was continued for additional 20 min at room temperature. The sequence specificity of the binding was confirmed in competition experiments using a 100-fold molar excess of either unlabeled homologous or heterologous oligonucleotides. For supershift-assays, nuclear extract was first incubated with 2 mg of antibody for 45 min at 41C in a reaction mixture. Then 20 ng/ml salmon sperm DNA was added and the reaction was continued for 5 min at room temperature followed by the addition of labeled E2F-1 oligonucleotide for 20 min at room temperature. DNA-protein complexes were resolved on 5.5% nondenaturing polyacrylamide (29 : 1 cross-linking ratio), dried and exposed overnight to Fuji super RX films.
Determination of mitochondrial membrane potential
To measure DC m , treated or untreated cells were incubated with 5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethylbenzimidazolylcarbocyanine iodide (JC-1, 5 mg/ml; FL-2) (Molecular Probes, Inc., Eugene, OR, USA) for 20 min at room temperature in the dark followed by analysis on a flow cytometer (FACScan). Specific loss of DC m was calculated as follows: (% experimental loss of DC m À% spontaneous loss of DC m )/(100À% spontaneous loss of DC m ) Â 100.
Preparation of mitochondria and western blot analysis
Cells were washed with PBS, buffer A (100 mM Sucrose, 1 mM EGTA, 20 mM MOPS ph 7.4), resuspended in five volumes of buffer B (buffer A þ 5% Percoll, 0.01% Digitonin, 1 mM PMSF and protease inhibitors (complete, Roche)) and left to swell on ice for 15 min. Cells were homogenized with 30 strokes of a Dounce homogenizer and centrifuged at 2500 g for 10 min at 41C. The supernatants were further centrifuged at 15 000 g for 15 min at 41C and the resulting pellets were resuspended in buffer C (300 mM Sucrose, 1 mM EGTA, 20 mM MOPS and protease inhibitors). Mitochondria enriched fractions (pellets resuspended in buffer C) and supernatants (cytosol and microsomes) were subjected to SDS-PAGE and Western blot analysis. Cytochrome c was detected with a monoclonal anticytochrome c antibody (Clone MK12, BD pharmingen). Monoclonal antibodies against Tim23 (clone 32) were from BD transduction
Receptor-Fc blocking experiments
HeLa cells were treated with 6 mM NaB for 24 h in the presence of 10 mg/ml soluble TRAIL-R2-Fc, TNF-R2-Fc, CD95-Fc fusion proteins or control mouse IgG1 antibodies. Subsequently, apoptosis was determined by analysis of DNA fragmentation according to the method described by Nicoletti et al. (1991) . Soluble TNF-R2-Fc and TRAIL-R2-Fc fusion proteins were from Apotech (Switzerland). Soluble CD95 Fc fusion proteins were described previously (Dhein et al., 1995) . The mouse IgG1 isotype control was obtained from BD Bioscience.
Surface staining
Cells (2 Â 10 5 ) were incubated with 1 mg/ml primary antibody for 15 min at 41C, washed with PBS, incubated another 15 min with phycoerythrin-labeled goat-anti-mouse antibodies (Dianova, Hamburg, Germany) and analysed by FACScan (Becton Dickinson, Heidelberg, Germany). The anti-TRAIL-R1 (HS101) and anti-TRAIL-R2 (HS201) monoclonal antibodies were from Apotech (Switzerland). The agonistic antiCD95mAb anti APO-1 were described elsewere (Trauth et al., 1989) .
Plasmids and transfection
HeLa cells (1 Â 10 5 ) were transfected by the calcium phosphate co-precipitation method (Chen and Okayama, 1987) using pSUPER-siRNA targeting p53 transcripts or the respective empty vector (Brummelkamp et al., 2002) as described in the figure legend.
